Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 1Epilepsy 1Drug Resistant Epilepsy 1

Interventions

Saline Solution 6Dexmedetomidine 5Sodium Chloride 4Temozolomide 3Sevoflurane 3Propofol 3Methotrexate 3Levetiracetam 3trametinib 2perampanel 2dabrafenib 2Sugammadex 2Neuroimaging 2Methylphenidate 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gentamicins 2Fluorescein 2Anesthesia, Inhalation 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1pembrolizumab 1pegvisomant 1olutasidenib 1naxitamab 1lorlatinib 1gadoterate meglumine 1gadobenic acid 1durvalumab 1dexketoprofen trometamol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Anticonvulsants × CNS × Clear all
NCT04650204 2023-06-22

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Mayo Clinic

Phase 4 Terminated
4 enrolled 9 charts
CNS

Drug Resistant Epilepsy, Epilepsy, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡